Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC.INTS · Entity 7853 | Chief Financial Officer | July 16, 2026 | July 20, 2026 |
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | SVP and CFO | January 13, 2020 | January 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTENSITY THERAPEUTICS, INC.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2036-07-16 | Direct | 34,000 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 34,000 · Balance 34,000 F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.
LISATA THERAPEUTICS, INC.
Report date January 13, 2020 · Filed January 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,435 |
Reported balance
After 2020-01-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-01-13 · Grant · Acquired 19,000 · Balance 64,435 F1: Represents 19,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. |
| Common StockSEC Table I · non-derivative | Direct | 61,834 |
Reported balance
After 2020-01-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-01-13 · Tax withholding · Disposed 2,601 · Balance 61,834 |
| Common StockSEC Table I · non-derivative | Direct | 59,644 |
Reported balance
After 2020-01-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-01-14 · Tax withholding · Disposed 2,190 · Balance 59,644 F2: Includes 25,575 unvested restricted stock awards. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2030-01-13 | Direct | 29,000 |
Reported balance
After 2020-01-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-13 · Grant · Acquired 29,000 · Balance 29,000 F3: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 19,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
F2: Includes 25,575 unvested restricted stock awards.
F3: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 20:02 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 34,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001524547-26-000009 · wk-form4_1784577756.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:08 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantCommon Stock, $0.0001 Par Value | 1,093 | $3.49 | $3,809.11 |
DisclosureSEC source: 0001524547-26-000007 · wk-form4_1782936500.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026. F3 · balance_after: On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:01 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantCommon Stock, $0.0001 Par Value | 14,482 | $0.26 | $3,794.28 |
DisclosureSEC source: 0001524547-26-000003 · wk-form4_1767646901.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,661 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:02 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantCommon Stock, $0.0001 Par Value | 14,179 | $0.26 | $3,700.72 |
DisclosureSEC source: 0001567264-25-000065 · wk-form4_1751486535.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,179 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:03 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 300,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000027 · wk-form4_1746561816.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:21 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 427,379 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001524547-24-000002 · wk-form4_1729714866.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,379 Underlying: Common Stock · 427,379 shares Expires 2034-10-21 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on October 21, 2024. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 13:17 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 80,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001213900-23-094886 · ownership.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-12-11 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four equal, annual installments, beginning on December 11, 2024. Read SEC document |
| January 14, 2020 Filed Jan 15, 2020 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 2,190 | $3.38 | $7,402.20 |
DisclosureSEC source: 0001524547-20-000005 · wf-form4_157912240103290.xml · nonDerivative · entry 3 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,644 F2 · balance_after: Includes 25,575 unvested restricted stock awards. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001524547-20-000005 · wf-form4_157912240103290.xml · derivative · entry 4 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2030-01-13 F3 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 2,601 | $3.28 | $8,531.28 |
DisclosureSEC source: 0001524547-20-000005 · wf-form4_157912240103290.xml · nonDerivative · entry 2 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,834 Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001524547-20-000005 · wf-form4_157912240103290.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,435 F1 · shares: Represents 19,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 1,821 | $2.83 | $5,153.43 |
DisclosureSEC source: 0001524547-20-000003 · wf-form4_157860399368878.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,435 F1 · balance_after: Includes 15,325 unvested restricted stock. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:22 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001524547-19-000009 · wf-form4_154767373106213.xml · derivative · entry 3 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-01-14 F3 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:22 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 2,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001524547-19-000009 · wf-form4_154767373106213.xml · nonDerivative · entry 2 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,256 F2 · balance_after: Includes 18,650 unvested restricted stock awards. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:22 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001524547-19-000009 · wf-form4_154767373106213.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,415 F1 · shares: Represents 16,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:42 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 1,795 | $4.64 | $8,328.80 |
DisclosureSEC source: 0001524547-19-000006 · wf-form4_154714213392249.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,415 F1 · balance_after: Includes 6,650 shares of unvested restricted stock. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:30 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 6,407 | $8.64 | $55,356.48 |
DisclosureSEC source: 0000320017-18-000078 · wf-form4_152961301286128.xml · nonDerivative · entry 2 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,210 F2 · balance_after: Includes 9,975 shares of unvested restricted stock. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:30 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 13,300 | $8.64 | $114,912.00 |
DisclosureSEC source: 0000320017-18-000078 · wf-form4_152961301286128.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,617 F1 · balance_after: Reflects 13,300 in performance rights, the criteria for which was satisfied on April 6, 2018 and which vested in full on June 20, 2018, when the shareholders voted to approve the new 2018 Equity Incentive Compensation Plan. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 22:57 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantPerformance Rights · Derivative | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-020001 · tv490822_4.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires not disclosed F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The performance criteria was satisfied on April 6, 2018 and the performance right shall vest in full on the date of stockholder approval of a new or amended equity plan provided that such approval is obtained on or prior to August 30, 2018 and if not obtained by such date this performance right shall terminate (the "Vesting Date"). F2 · derivative.expiration_date: The performance criteria was satisfied on April 6, 2018 and the performance right shall vest in full on the date of stockholder approval of a new or amended equity plan provided that such approval is obtained on or prior to August 30, 2018 and if not obtained by such date this performance right shall terminate (the "Vesting Date"). Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001144204-18-001703 · tv483052_4.xml · derivative · entry 3 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-08 F3 · derivative.exercise_date: One-third of the shares underlying the stock options vest immediately on the grant date, with an additional one-third vesting on each of the first and second anniversaries of the grant date. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 1,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001703 · tv483052_4.xml · nonDerivative · entry 2 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,317 F2 · balance_after: Includes 9,975 shares of unvested restricted stock. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001703 · tv483052_4.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,120 F1 · shares: Represents 13,300 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. The restricted stock vests in three equal installments, with one-third of the shares vesting on the date of grant and an additional one-third vesting on each of the first and second anniversaries of the grant date. F2 · balance_after: Includes 9,975 shares of unvested restricted stock. Read SEC document |
| May 18, 2017 Filed May 22, 2017 20:28 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 5,982 | $5.13 | $30,687.66 |
DisclosureSEC source: 0001144204-17-028881 · v467614_4.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,619 Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 20:23 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 214 | $4.74 | $1,014.36 |
DisclosureSEC source: 0001144204-17-022666 · v465292_form4.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,601 F1 · balance_after: Includes 14,003 shares of unvested restricted stock. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 22:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 239 | $3.87 | $924.93 |
DisclosureSEC source: 0001144204-17-004360 · v457629_4.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,812 F1 · balance_after: Includes 14,613 shares of unvested restricted stock. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:48 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001144204-17-001860 · v456766_4.xml · derivative · entry 3 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-09 F3 · security: 25% of the shares underlying the stock options vest immediately on the grant date and the remaining 75% of the shares underlying the stock options will vest annually over the following three years. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:48 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 1,672 | $3.54 | $5,918.88 |
DisclosureSEC source: 0001144204-17-001860 · v456766_4.xml · nonDerivative · entry 2 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,051 F2 · balance_after: Includes 15,088 shares of unvested restricted stock. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:48 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-001860 · v456766_4.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,723 F1 · shares: Represents 13,300 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. 25% of the shares of restricted stock vest immediately on the grant date and the remaining 75% of the shares of restricted stock will vest annually over the following three years. F2 · balance_after: Includes 15,088 shares of unvested restricted stock. Read SEC document |
| October 25, 2016 Filed Nov 10, 2016 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 176 | $4.12 | $725.12 |
DisclosureSEC source: 0001144204-16-133280 · v452731_4.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,423 F1 · balance_after: Includes 5,254 shares of unvested restricted stock. Read SEC document |
| September 29, 2016 Filed Sep 30, 2016 20:32 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option · Derivative | 13,377 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001144204-16-126315 · v449787_4.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,377 Underlying: Common Stock · 13,377 shares Expires 2026-09-29 F1 · security: These stock options were granted upon the Company's Compensation Committee approval on September 29, 2016, in consideration of the unpaid portion of the reporting person's discretionary 2015 target bonus. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.